newsfilter
← Latest News
GlobeNewswire·

Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE

MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,